Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

医学 伊马替尼 甲磺酸伊马替尼 内科学 中止 累积发病率 胃肠病学 随机对照试验 髓系白血病 外科 肿瘤科 核医学 队列
作者
Rüdiger Hehlmann,Martin C. Müller,Michael Lauseker,Benjamin Hanfstein,Alice Charlotte Fabarius,Annette Schreiber,Ulrike Proetel,Nadine Pletsch,Markus Pfirrmann,Claudia Haferlach,Susanne Schnittger,Hermann Einsele,Jolanta B. Dengler,Christiane Falge,Lothar Kanz,Andreas Neubauer,Michael Kneba,Frank Stegelmann,Michael G. Pfreundschuh,Cornelius Florian Waller
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:32 (5): 415-423 被引量:321
标识
DOI:10.1200/jco.2013.49.9020
摘要

PURPOSE: Deep molecular response (MR(4.5)) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after treatment discontinuation. It is unclear how many patients achieve MR(4.5) under different treatment modalities and whether MR(4.5) predicts survival. PATIENTS AND METHODS: Patients from the randomized CML-Study IV were analyzed for confirmed MR(4.5) which was defined as ≥ 4.5 log reduction of BCR-ABL on the international scale (IS) and determined by reverse transcriptase polymerase chain reaction in two consecutive analyses. Landmark analyses were performed to assess the impact of MR(4.5) on survival. RESULTS: Of 1,551 randomly assigned patients, 1,524 were assessable. After a median observation time of 67.5 months, 5-year overall survival (OS) was 90%, 5-year progression-free-survival was 87.5%, and 8-year OS was 86%. The cumulative incidence of MR(4.5) after 9 years was 70% (median, 4.9 years); confirmed MR(4.5) was 54%. MR(4.5) was reached more quickly with optimized high-dose imatinib than with imatinib 400 mg/day (P = .016). Independent of treatment approach, confirmed MR(4.5) at 4 years predicted significantly higher survival probabilities than 0.1% to 1% IS, which corresponds to complete cytogenetic remission (8-year OS, 92% v 83%; P = .047). High-dose imatinib and early major molecular remission predicted MR(4.5). No patient with confirmed MR(4.5) has experienced progression. CONCLUSION: MR(4.5) is a new molecular predictor of long-term outcome, is reached by a majority of patients treated with imatinib, and is achieved more quickly with optimized high-dose imatinib, which may provide an improved therapeutic basis for treatment discontinuation in CML.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
wwwww发布了新的文献求助10
2秒前
2秒前
zt发布了新的文献求助10
2秒前
3秒前
幸运海星完成签到,获得积分10
3秒前
lx的应助被huliqun采纳,获得20
3秒前
yeo完成签到 ,获得积分10
4秒前
4秒前
5秒前
风筝与亭发布了新的文献求助10
6秒前
6秒前
傅可正发布了新的文献求助10
7秒前
7秒前
安静的幻儿完成签到,获得积分10
8秒前
Yangdandan发布了新的文献求助20
8秒前
韩han完成签到,获得积分10
9秒前
hehe_733发布了新的文献求助10
9秒前
CAOHOU的应助被hsj采纳,获得10
9秒前
10秒前
26发布了新的文献求助10
12秒前
fengjingjing发布了新的文献求助10
13秒前
小马甲的应助被天天采纳,获得10
15秒前
酷酷的仇天完成签到,获得积分10
16秒前
16秒前
17秒前
超现实牛马完成签到,获得积分10
18秒前
今天完成签到,获得积分10
19秒前
Ava的应助被LZ采纳,获得30
20秒前
传奇3的应助被LZ采纳,获得10
20秒前
无极微光的应助被心灵美雅霜采纳,获得20
21秒前
21秒前
Lesley发布了新的文献求助10
22秒前
Akim的应助被好运常伴采纳,获得10
24秒前
25秒前
彭于晏的应助被fengjingjing采纳,获得10
26秒前
26秒前
可爱的函函的应助被wwwww采纳,获得10
28秒前
Orange的应助被Omni采纳,获得10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191198
求助须知:如何正确求助?哪些是违规求助? 9578129
关于积分的说明 21856860
捐赠科研通 7790454
什么是DOI,文献DOI怎么找? 3436543
关于科研通互助平台的介绍 2560339
邀请新用户注册赠送积分活动 2483298